FDA Drug Approvals, January–April 2012

Get Permission

  • FDAlogoImatinib mesylate tablets (Gleevec) approved for the adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive gastrointestinal stromal tumors (GIST).
  • Vismodegib capsules (Erivedge) approved for the treatment of metastatic basal cell carcinoma or locally advanced basal cell carcinoma. 
  • Axitinib tablets (Inlyta) for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.
  • Glucarpidase  injection (Voraxaze) for the treatment of toxic plasma methotrexate concentrations (> 1 μmol/L) in patients with delayed methotrexate clearance due to impaired renal function.

For more information, visit fda.gov.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.